Finance

Lists
PACS:NYSE
PACS Group Inc
USD 46,39
-1,11%
(-0,52) 1D
19 Okt., 12:50:44 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PACS...
Open
USD 47,02
High
USD 48,00
Low
USD 46,37
Mkt. cap
7,35 mjd
Avg. vol.
802,41 k
Volume
157,52 k
P/E ratio
27,80
52-wk high
USD 49,49
52-wk low
USD 10,31
EPS
USD 1,67
Shares outstanding
158,34 m
No. of employees
47 k
Open
USD 47,02
High
USD 48,00
Low
USD 46,37
Mkt. cap
7,35 mjd
Avg. vol.
802,41 k
Volume
157,52 k
P/E ratio
27,80
52-wk high
USD 49,49
52-wk low
USD 10,31
EPS
USD 1,67
Shares outstanding
158,34 m
No. of employees
47 k
News stories
From web sources and news partners
About PACS Group Inc
CEO-
Employees47,5 k
Founded2013
HeadquartersSalt Lake City, Utah, Verenigde State van Amerika
SectorHealth care provider
Websitepacs.com
Analyst ratings
Based on 5 analysts giving stock ratings to PACS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PACS in the last 3 months.
Highest
Current USD 46,39
USD 60,00 (+29,34%)
Average
USD 58,00 (+25,03%)
Lowest
USD 57,00 (+22,87%)
Analyst
Recommendation
Action
Price target
Projected
Date
A.J. Rice
UBS
Buy
Maintained
USD 60,00
+29,3%
10/12/2026
Benjamin Rossi
J.P. Morgan
Buy
Reiterated
USD 58,00
+25%
09/08/2026
David S Macdonald
Truist Financial
Buy
Maintained
-
-
09/02/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
USD 57,00
+22,9%
08/10/2026
Ben Hendrix
RBC Capital
Buy
Reiterated
USD 57,00
+22,9%
08/05/2026
Jailendra Singh
Truist Financial
Buy
Reiterated
USD 52,00
+12,1%
06/15/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
USD 0,63 / USD 0,56
+11,71%beat
Revenue / Est. (USD)
1,43 mjd / 1,41 mjd
+1,00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,34 mjd
1,36 mjd
1,42 mjd
1,43 mjd
Cost of goods sold
1,13 mjd
1,12 mjd
1,16 mjd
1,17 mjd
Cost of revenue
1,13 mjd
1,12 mjd
1,16 mjd
1,17 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
112,44 m
123,29 m
122,45 m
124,74 m
Operating expense
126,84 m
138,67 m
140,52 m
144,86 m
Total operating expenses
1,26 mjd
1,26 mjd
1,30 mjd
1,32 mjd
Operating income
86,27 m
94,69 m
120,04 m
109,33 m
Other non operating income
-956,00 k
-99,00 k
-330,00 k
1,82 m
EBT including unusual items
76,30 m
86,81 m
113,74 m
105,84 m
EBT excluding unusual items
76,30 m
86,81 m
113,74 m
105,84 m
Income tax expense
23,97 m
27,03 m
33,07 m
29,49 m
Effective tax rate
31,41%
31,13%
29,07%
27,86%
Other operating expenses
-
-
-
-
Net income
52,41 m
59,70 m
80,70 m
76,37 m
Net profit margin
3,90%
4,40%
5,68%
5,35%
Earnings per share
0,45
0,57
0,64
0,63
Interest and investment income
-
-
-
-
Interest expense
-8,53 m
-8,58 m
-6,42 m
-6,04 m
Net interest expenses
-8,53 m
-8,58 m
-6,42 m
-6,04 m
Depreciation and amortization charges
14,40 m
15,38 m
18,08 m
20,12 m
EBITDA
100,67 m
110,07 m
138,11 m
129,45 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme